<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9771">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05690581</url>
  </required_header>
  <id_info>
    <org_study_id>CM369-001</org_study_id>
    <nct_id>NCT05690581</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>A Nonrandomized, Open-label, Multicenter, Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing InnoCare Pharma Tech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing InnoCare Pharma Tech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a nonrandomized, open-label, multicenter, phase I clinical trial to evaluate the&#xD;
      safety, tolerability, pharmacokinetic characteristics, and efficacy of CM369 in subjects with&#xD;
      advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2023</start_date>
  <completion_date type="Anticipated">April 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>90 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse events (SAEs)</measure>
    <time_frame>90 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose limiting toxicities (DLTs)</measure>
    <time_frame>90 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Peak Time (Tmax)</measure>
    <time_frame>90 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Half-life (t1/2)</measure>
    <time_frame>90 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Area Under the Curve (AUC)</measure>
    <time_frame>90 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: Clearance (CL)</measure>
    <time_frame>90 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Apparent volume of distribution of steady state (Vss)</measure>
    <time_frame>90 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Incidence of anti-CM369 antibody</measure>
    <time_frame>90 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>CM369 Ia Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of CM369 as monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CM369 Ib Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose expansion of CM369 as monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CM369</intervention_name>
    <description>Specified dose on specified days.</description>
    <arm_group_label>CM369 Ia Dose Escalation</arm_group_label>
    <arm_group_label>CM369 Ib Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Life expectancy â‰¥12 weeks.&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group performance status of 0-1.&#xD;
&#xD;
          3. Subjects with cytology and/or histologically confirmed locally advanced unresectable&#xD;
             or metastatic solid tumors.&#xD;
&#xD;
          4. Agree to provide archived tumor tissue samples of primary or metastatic lesions.&#xD;
&#xD;
          5. Phase Ia: have at least one measurable lesion or one evaluable lesion according to&#xD;
             RECIST 1.1.&#xD;
&#xD;
          6. Have adequate organ function as described in the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with primary central nervous system (CNS) tumors or unstable CNS metastases.&#xD;
&#xD;
          2. Subjects who have uncontrollable or major cardiovascular disease refer to protocol.&#xD;
&#xD;
          3. Subjects who have an active autoimmune disease or have had an autoimmune disease with&#xD;
             risk of recurrence.&#xD;
&#xD;
          4. Subjects who have active or history of interstitial lung disease or non-infectious&#xD;
             pneumonia.&#xD;
&#xD;
          5. Subjects with any active infection requiring systemic treatment by intravenous&#xD;
             infusion within 14 days prior to the first administration of the study drug.&#xD;
&#xD;
          6. HIV infection; Hepatitis C virus (HCV) antibody positive; HCV infection.&#xD;
&#xD;
          7. History of active bleeding within 2 months before screening, or bleeding symptoms&#xD;
             associated with application of anticoagulant drugs or other interventions.&#xD;
&#xD;
          8. Have not recovered to CTCAE Grade 1 or better from the adverse events due to previous&#xD;
             cancer therapies.&#xD;
&#xD;
          9. Subjects who received systemic immunosuppressive drugs within 14 days prior to the&#xD;
             first administration of the study drug.&#xD;
&#xD;
         10. Subjects who require systemic treatment of corticosteroids or other immunosuppressive&#xD;
             agents within 14 days prior to first dose.&#xD;
&#xD;
         11. Has a history of severe allergic reactions to monoclonal antibodies.&#xD;
&#xD;
         12. Subjects with any mental or cognitive impairment that may limit their understanding,&#xD;
             implementation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ruihua Xu</last_name>
    <phone>13922296676</phone>
    <email>xurh@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruihua Xu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ying Cheng</last_name>
      <phone>0431-80596315</phone>
      <email>JL.Cheng@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>January 10, 2023</study_first_submitted>
  <study_first_submitted_qc>January 18, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2023</study_first_posted>
  <last_update_submitted>March 1, 2023</last_update_submitted>
  <last_update_submitted_qc>March 1, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

